{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:34:46Z","timestamp":1790372086894,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["ZL2024H013"],"award-info":[{"award-number":["ZL2024H013"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L242036"],"award-info":[{"award-number":["L242036"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371458"],"award-info":[{"award-number":["32371458"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028907","name":"Organic Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028907","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114383","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:47:38Z","timestamp":1762012058000},"page":"114383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P2","title":["mRNA nanomedicine reprograms the cell cycle to increase the effectiveness of targeted therapy for HER2-low breast cancers"],"prefix":"10.1016","volume":"388","author":[{"given":"Nan-Nan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Han","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Jia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo-Xi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114383_bb0010","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0015","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114383_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114383_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","article-title":"Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives","volume":"21","author":"Marra","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.jconrel.2025.114383_bb0030","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","article-title":"Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.jconrel.2025.114383_bb0040","doi-asserted-by":"crossref","first-page":"15668","DOI":"10.1021\/acsnano.4c18153","article-title":"Chimeric antigen receptor-engineered cell membrane-coated nanoparticles promote dual-targeted mRNA-based cancer gene therapy","volume":"19","author":"Lei","year":"2025","journal-title":"ACS Nano"},{"issue":"13","key":"10.1016\/j.jconrel.2025.114383_bb0045","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1021\/acsnano.3c13038","article-title":"Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B\/CD 4 T cell crosstalk","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"issue":"17","key":"10.1016\/j.jconrel.2025.114383_bb0050","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0055","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1038\/s41467-023-43324-w","article-title":"Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer","volume":"14","author":"Tarantino","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114383_bb0060","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery","volume":"20","author":"Levine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114383_bb0065","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7912","key":"10.1016\/j.jconrel.2025.114383_bb0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41586-022-04696-z","article-title":"Fundamental immune-oncogenicity trade-offs define driver mutation fitness","volume":"606","author":"Hoyos","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jconrel.2025.114383_bb0080","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ccell.2023.09.006","article-title":"Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden","volume":"41","author":"Zhu","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0085","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-023-42458-1","article-title":"Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth","volume":"14","author":"Tombari","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114383_bb0090","first-page":"564","article-title":"Specific regulation of BACH1 by the hotspot mutant p53(R175H) reveals a distinct gain-of-function mechanism","volume":"4","author":"Su","year":"2023","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0095","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1038\/s41467-024-47606-9","article-title":"Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling","volume":"15","author":"Hobor","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114383_bb0100","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114383_bb0105","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1021\/acsnano.4c16562","article-title":"Apolipoprotein fusion enables spontaneous functionalization of mRNA lipid nanoparticles with antibody for targeted cancer therapy","volume":"19","author":"Park","year":"2025","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.jconrel.2025.114383_bb0110","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114383_bb0115","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jconrel.2024.04.018","article-title":"Cardiac delivery of modified mRNA using lipid nanoparticles: cellular targets and biodistribution after intramyocardial administration","volume":"369","author":"Labonia","year":"2024","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114383_bb0120","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114383_bb0125","article-title":"Lipid nanoparticles with fine-tuned composition show enhanced colon targeting as a platform for mRNA therapeutics","volume":"12","author":"Rampado","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.114383_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114018","article-title":"Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma","volume":"385","author":"Shumer-Elbaz","year":"2025","journal-title":"J. Control. Release"},{"issue":"22","key":"10.1016\/j.jconrel.2025.114383_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309770","article-title":"All-trans-retinoic acid-adjuvanted mRNA vaccine induces mucosal anti-tumor immune responses for treating colorectal Cancer","volume":"11","author":"Li","year":"2024","journal-title":"Adv. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114383_bb0140","article-title":"The clinical progress and challenges of mRNA vaccines","volume":"15","author":"Yu","year":"2023","journal-title":"Wiley Interdiscip. Rev.\u202f:Nanomed. Nanobiotech."},{"key":"10.1016\/j.jconrel.2025.114383_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102013","article-title":"Delivery of mRNA for cancer therapy: progress and prospects","volume":"53","author":"Su","year":"2023","journal-title":"Nano Today"},{"issue":"12","key":"10.1016\/j.jconrel.2025.114383_bb0150","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1007\/s12274-023-6238-5","article-title":"RNA-based nanomedicines and their clinical applications","volume":"16","author":"Su","year":"2023","journal-title":"Nano Res"},{"issue":"599","key":"10.1016\/j.jconrel.2025.114383_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114383_bb0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","article-title":"Enhancing RNA-lipid nanoparticle delivery: organ- and cell-specificity and barcoding strategies","volume":"375","author":"Wei","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41565-024-01747-6","article-title":"Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery","volume":"20","author":"Xue","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114383_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01373-0","article-title":"Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles","author":"Liu","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0175","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1038\/s41467-024-53914-x","article-title":"Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114383_bb0180","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","article-title":"Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance","volume":"21","author":"Waks","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114383_bb0185","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: an insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"issue":"27","key":"10.1016\/j.jconrel.2025.114383_bb0190","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114383_bb0195","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","article-title":"Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines","volume":"18","author":"Han","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"26","key":"10.1016\/j.jconrel.2025.114383_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202405444","article-title":"One-component cationic lipids for systemic mRNA delivery to splenic T cells","volume":"63","author":"Zhang","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2025.114383_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.067","article-title":"Surfactant protein B-derived peptides as endosomal escape enhancers for pulmonary delivery of siRNA","volume":"381","author":"Herman","year":"2025","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114383_bb0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.23.02768","article-title":"Clinical and molecular characteristics of high-risk, recurrent, or metastatic endometrial cancer that is human epidermal growth factor receptor 2-low","volume":"43","author":"Van Dijk","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114383_bb0215","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","article-title":"Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity","volume":"39","author":"Hanker","year":"2021","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114383_bb0220","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.annonc.2022.08.001","article-title":"Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma","volume":"33","author":"Augustin","year":"2022","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114383_bb0225","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12520","article-title":"Cell fate regulation governed by p53: friends or reversible foes in cancer therapy","volume":"44","author":"Song","year":"2024","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0230","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","article-title":"The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114383_bb0235","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114383_bb0240","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114383_bb0245","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","article-title":"Towards precision oncology with patient-derived xenografts","volume":"19","author":"Zanella","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:57:35Z","timestamp":1780822655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"alternative-id":["S0168365925009976"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114383","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA nanomedicine reprograms the cell cycle to increase the effectiveness of targeted therapy for HER2-low breast cancers","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114383"}}